EVOTEC AND SECARNA COLLABORATE ON ANTISENSE OLIGONUCLEOTIDES (ASO) DRUG DISCOVERY
THE EVOTEC — SECARNA COLLABORATION

Mission
- Jointly working on projects for a co-owned pipeline across a broad range of different indications
- Both parties will combine their state-of-the-art platforms to maximise the efficiency and power to identify new antisense therapeutics

Agreement
- Joint long-term multi-target drug discovery alliance
- Secarna provides its proprietary LNAplus™-based antisense molecules for the collaboration
- Evotec is responsible for further development of these molecules and subsequent partnering
- Projects will be co-owned
- Evotec’s partners can access antisense therapeutics through a variety of individual deal structures

BROADENING THE MULTIMODALITY “AUTOBAHN”

Cutting-edge antisense drug discovery capabilities and capacities through the collaboration between SECARNA and EVOTEC
Antisense therapy is a form of treatment that is clearly distinguished from traditional approaches such as small molecule or antibody-based approaches. While the latter modulate (suppress or activate) the function of an existing protein target, ASOs interfere with the production of the protein. ASOs are short chemically modified DNA-strands that are designed to be complementary to the target (pre)mRNA.

By binding to the target (pre)mRNA followed by degradation of the (pre)mRNA ASOs suppress target expression. ASOs can also be directed against long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) and used for modulation of downstream gene expression. Furthermore, mRNA splicing can be modulated by ASOs directed against regions involved in splicing processes. With these different possibilities ASOs can be directed against a broad variety of targets, also those which are considered undruggable on the protein level.

Since the genetic information of most organisms is known, the design of ASOs is a rational, fast and efficient process.
Secarna has developed technical capabilities and expertise in the discovery and development of third-generation antisense therapeutics.

**Present the technology and the uniqueness**

**Antisense oligonucleotides fill a position not or insufficiently addressed by more traditional approaches**

**Address undruggable targets**
- Inaccessible to antibodies
- Without function/surface that can be targeted by small molecules

**Address challenging targets**
- Selective inhibition of targets with high structural homology to unwanted off-targets

**Proven for different modes of administration**

**Direct patient treatment**
- Unique and well-characterised biodistribution and pharmacokinetics
- Can be manipulated by conjugation to targeting moieties

**Ex Vivo treatment of cells in the setting of cell therapies**
- Transient target knockdown

**Ex Vivo to improve:**
- Manufacturing process
- Safety of cell product
- Efficacy of cell product

**Systemic treatment**
- Intravenous infusion
- Subcutaneous injection

**Local treatment**
- Intrathecal
- Intravitreal
- Inhalation
For systemic administration:
- Exceptional target knockdown by unconjugated and unformulated ASOs in tissues with strong biodistribution such as liver and kidney
- Good target knockdown achievable in a variety of other tissues including tumors
- In contrast to siRNA no delivery system required in vivo and in vitro

For ex vivo applications:
- Potent target knockdown achievable without delivery system and without impairment of cell viability in multitude of cells suitable for cell therapy
- Target knockdown can last for > 7 days after removal of ASO
Rapid and efficient generation of highly active and well-tolerated LNAplus™ candidates as key competitive advantage

- Application of stringent filtering criteria during Oligofyer™ bioinformatic selection process strongly reduces the number of compounds tested in wet screens by elimination of unspecific, potentially toxic or inactive compounds
- Multitude of well-characterised cell-based screening assays established at Secarna covering major disease indications
- Elimination of potentially toxic compounds early during compound characterisation step. Most relevant toxicities are covered

- Target- and disease-tailored investigation of in vitro proof of concept in sophisticated cell-based assays
- Selection of most tolerated compounds in vivo
- Hit-to-lead optimisation possible – if required – at certain steps

LNAplus™ has already been validated by development pipeline and several commercial partnering transactions
Evotec & Secarna –
A perfect fit of capacities and capabilities

If you want to know more about the alliance or our ASO capabilities and capacities, please contact:
info@evotec.com or info@secarna.com